Early Promise Of NextCure’s Novel IO Candidate Continues To Fade

NextCure, Inc. got off to a strong start, with the best-performing initial public offering in the US in 2019 and rising to six times its initial stock price in November based on two responses in lung cancer patients treated with NC318, its novel immuno-oncology candidate. However, the company’s value has sunk based on updates since then, including a 13 July announcement that it will not advance the NSCLC and ovarian cancer cohorts of an ongoing Phase I/II clinical trial into the Phase II portion of the study.

Beltsville, MD-based NextCure said it made that decision based on current enrollment criteria and clinical response data in its all-comer study